Top Machine Learning Companies in San Diego, CA (64)

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Strong Revenue Growth: Revenue is described as scaling from roughly $3M to about $80M over the last few years, with Inc. 5000 recognition citing a three‑year surge. Ongoing federal awards and ACV disclosures further point to continued top‑line expansion into 2025–2026.

Profitability: Profitability is reported as achieved and sustained over multiple recent years, indicating growth without heavy burn. Claims of closing ~$80M in ACV alongside profitability reinforce durable unit economics.

Market Expansion: A DIU prototype transitioned to a production vehicle with a ceiling near $99M and procurement trackers show FY2025–FY2026 awards, signaling broader adoption across DoD units. Active hiring, expanding deployments, and mentions of footprints abroad suggest widening reach.

Strong Revenue Growth: Revenue is on a clear upward trajectory, with estimates rising from 2024 through 2025, leadership guiding to a substantially larger 2026, and a stated path toward $1B by 2028. This momentum is tied to increasing orders, expanding programs, and a growing mix of software and systems.

Investor Backing & Capital Strength: A multi‑billion‑dollar capital package closed in March 2026, including a $1.5B Series G at a $12.7B valuation plus additional preferred equity and a delayed‑draw facility. This financing depth provides runway to scale autonomy software, aircraft programs, and the Aechelon acquisition.

Market Expansion: Operations and sales expanded internationally with new contracts across allies including Romania, Japan, Greece, and Canada, while U.S. traction includes Air Force CCA autonomy selections and a Navy contract to further develop X‑BAT. Over time, these moves broaden geographic reach and platform adoption.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Product Line Growth: Launched and acquired products are expanding at a double‑digit pace (e.g., +18% operational in Q2 2026), led by assets such as Eliquis, Padcev, the Vyndaqel family, and Lorbrena. Excluding Comirnaty and Paxlovid, revenue grew mid‑single digits, signaling healthy momentum in the core portfolio.

Cost & Operational Efficiency: A multi‑year cost realignment targets about $5.7B in net savings by end‑2026, with a further $2.5B in productivity gains planned for 2027–2029. These actions have supported improved adjusted earnings even as headline revenue normalizes post‑COVID.

Innovation-Driven Growth: A robust late‑stage pipeline and oncology expansion following the Seagen acquisition underpin future growth, with numerous pivotal study starts in 2025–2026. Company commentary highlights oncology and obesity programs as key catalysts into the back half of the decade.

Strong Hiring & Retention: Hiring momentum, explicit “rapid growth” language on the careers page, and ongoing requisitions across Woburn/Boston, Arlington, Dayton, Melbourne, and San Diego point to expanding teams and stable retention. LinkedIn and careers postings indicate an active build-out across engineering and related functions.

Innovation-Driven Growth: Recent U.S. Navy awards, continued DARPA work through at least early 2026, and progress on multi‑phase programs (e.g., AIR and other DARPA initiatives) indicate expansion fueled by advanced R&D in AI/ML, sensing, cyber/EW, and mission software. Follow‑on options and modifications suggest programs are maturing rather than winding down.

Market Expansion: A five‑site U.S. footprint and active recruiting across these locations reflect scaled operations beyond a single hub. Participation on large DoD IDIQ vehicles and industry engagement (e.g., a CVPR 2026 workshop sponsorship) point to a widening market presence.

Market Expansion: Expansion into ten U.S. cities, new depots in Dallas and Phoenix, and a Scottsdale command center indicate a broadening operational footprint. Public rides in Las Vegas and San Francisco with over one million autonomous miles signal readiness to scale into paid service pending approvals.

Strategic Partnerships: A multi-year integration with Uber starting in Las Vegas in 2026 (and Los Angeles in 2027) expands distribution and rider access. Venue tie-ups in Las Vegas and supplier arrangements support commercialization as the fleet scales.

Investor Backing & Capital Strength: Amazon ownership and a new Bay Area manufacturing facility reflect strong capital support to ramp production and operations. Ongoing hiring and production plans for 2026 underscore resourcing for the transition to paid service.

Strong Market Position & Advantage: Independent industry tracking places Oura as the dominant smart‑ring vendor, maintaining leadership even as new entrants scale. Shipment growth for the category accelerated while Oura remained the leader.

Strong Revenue Growth: Company and third‑party reports indicate revenue roughly doubled in 2024 with guidance to surpass prior levels in 2025, alongside a sharp acceleration in unit sales. Recent disclosures cite more than half of cumulative sales occurring in the prior year.

Investor Backing & Capital Strength: Late‑2025 fundraising at a significantly higher valuation and substantial capital raised point to strong investor confidence. Added partnerships and ecosystem integrations, including glucose insights collaborations, reinforce access to resources.

Strong Market Position & Advantage: Altera is widely characterized as one of the two dominant FPGA vendors, with notable strength in high‑end Agilex devices and a broad, refreshed portfolio. This standing is reinforced by its re‑emergence as the largest independent pure‑play FPGA company and leadership’s intent to take share from AMD/Xilinx.

Product Line Growth: Since separation, the company has expanded Agilex families (e.g., Agilex 5/3/7) and advanced its Quartus/FPGA AI tooling to address edge through data‑center use cases. These launches and updates indicate sustained investment aimed at enlarging addressable markets and improving time‑to‑market.

Investor Backing & Capital Strength: The 2025 majority investment by Silver Lake, with Intel retaining a significant stake, establishes a well‑capitalized, standalone structure. This ownership setup is positioned to accelerate roadmap execution and innovation across high‑growth segments like AI/data centers and 5G.

Strong Revenue Growth: External accolades indicate outsized multi‑year revenue expansion, including being named Adweek’s 2023 #1 Fastest Growing Agency and ranking No. 58 on the 2024 Inc. 5000. Leadership communications reference continued momentum into 2026, reinforcing a trajectory of ongoing top‑line gains.

Innovation-Driven Growth: Capability buildouts in AI and automation—such as launching Catapult and acquiring BotsCrew—align offerings to rising client demand for AI agents and automation. These investments broaden the firm’s digital transformation remit and strengthen its growth platform.

Market Expansion: Enterprise‑level remits and federal wins, including a direct AOR role with the U.S. Air Force Rapid Sustainment Office, show reach beyond project work. Multiple U.S. offices, a rising LinkedIn headcount band, and a larger Cincinnati footprint point to a widening geographic presence.